BAUDETTE, Minn., Sept. 27, 2016 /PRNewswire/ -- ANI
Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Erythromycin Ethylsuccinate for Oral Suspension
200mg/5mL indicated as a treatment for various infections. The current annual U.S. market for this product is approximately
$78 million, according to IMS Health, and is representative of two brand products. ANI will
immediately launch the product.
Arthur S. Przybyl, ANI's President and CEO stated, "This is the first product that we are
launching from the basket of 22 previously marketed generic products that we acquired in July 2015
and it represents another successful manufacturing site transfer and re-commercialization of a previously discontinued ANDA
product. ANI has added nine new products to our commercial portfolio in 2017 and we continue to forecast the launch of at
least one additional generic product this year."
About Erythromycin Ethylsuccinate for Oral Suspension
Erythromycin Ethylsuccinate for Oral Suspension is indicated in the treatment of infections caused by susceptible strains of
selected diseases. For more information, including the complete list of indications and usages, please see the accompanying Full
Prescribing Information.
About ANI
ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an integrated specialty pharmaceutical company developing,
manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product
development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving
extended release and combination products. For more information, please visit our website www.anipharmaceuticals.com.
Forward-Looking Statements
To the extent any statements made in this release deal with information that is not historical, these are forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not
limited to, statements about price increases, the Company's future operations, products financial position, operating
results and prospects , the Company's pipeline or potential markets therefor, and other statements that are not historical in
nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "plans," "potential," "future,"
"believes," "intends," "continue," other words of similar meaning, derivations of such words and the use of future dates.
Uncertainties and risks may cause the Company's actual results to be materially different than those expressed in or implied
by such forward-looking statements. Uncertainties and risks include, but are not limited to, the risk that the Company may face
with respect to importing raw materials; increased competition; acquisitions; contract manufacturing arrangements; delays or
failure in obtaining product approval from the U.S. Food and Drug Administration; general business and economic conditions;
market trends; products development; regulatory and other approvals and marketing.
More detailed information on these and additional factors that could affect the Company's actual results are described in the
Company's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and quarterly
reports on Form 10-Q, as well as its proxy statement. All forward-looking statements in this news release speak only as of the
date of this news release and are based on the Company's current beliefs, assumptions, and expectations. The Company undertakes
no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or
otherwise.
For more information about ANI, please contact:
Investor Relations
IR@anipharmaceuticals.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ani-pharmaceuticals-announces-launch-of-erythromycin-ethylsuccinate-for-oral-suspension-200mg5ml-300334595.html
SOURCE ANI Pharmaceuticals, Inc.